Thankfully, telomere shortening causes them to mutate and mutation triggers self-destruction. What we want is to preserve the critical stem cells.
For those wanting a more in-depth understanding of how TA-65 might work, I refer to you an email conversation I had with a patient, who was concerned that a blog referenced a Blasco paper demonstrating a 50% increase in liver cancer in mice after taking TA-65.
We were both pleased to learn that his test in October of 2014 showed a median length of 9,500 base pairs (or up to 25 years improvement) and a reduction to 8.3% critically-shortened telomeres (or a 38% relative reduction):
This is the conclusion of our interview with Telomere expert, Dr. Sandy Chang, MD, PhD from Yale University. He was interviewed by Dr. Ed Park at the American Academy of Anti-Aging Conference in 2014.
In this segment, Dr. Chang discusses the science linking shortened telomeres to cancer formation with an emphasis on his area of expertise, the SHELTERIN complex that protects the telomere itself.
For #ScienceSunday, we turn to a recent article published online showing that a modified mRNA version of the telomerase protein (TERT) can extend the telomeres in a dose-dependent fashion. This method has the advantage of not being permanent, as with gene therapy.
DISCLAIMER: This website is for educational purposes only and is not for advertising. Telomerase activators and nanovesicles are not FDA-approved to prevent or treat any disease and anecdotes are not scientific proof of efficacy. All patients were treated in the context of a fully informed and legally-protected patient physician relationship.
Required fields
© 2020 Recharge Biomedical
Exosomes and TA-65 are not FDA-approved to prevent or treat any illness
